Investors undeterred by NPS Natpara trial violations, risks
This article was originally published in Scrip
Executive Summary
Not even the FDA throwing out data after determining it was unreliable because of what it called "multiple and significant" violations at one clinical trial site across several studies, including the pivotal trial, for NPS Pharmaceuticals' hypoparathyroidism drug Natpara (recombinant human parathyroid hormone 1-84) was enough to deter investors on 10 September.